先期化疗联合术后腹腔热灌注化疗治疗晚期卵巢癌效果观察  

Efficacy observation of primary chemotherapy combined with postoperative intraperitoneal hyperthermic perfusion chemotherapy for treatment of advanced ovarian cancer

作　　者：王沛[1] 赵晓华[1] 王晓燕[1] Wang Pei;Zhao Xiaohua;Wang Xiaoyan(Department of Gynecology 1,Shanxi Provincial Cancer Hospital,Taiyuan 030013,China)

机构地区：[1]山西省肿瘤医院妇一科,太原030013

出　　处：《肿瘤研究与临床》2018年第6期384-387,共4页Cancer Research and Clinic

基　　金：山西省自然科学基金（2013011045-4）

摘　　要：目的 分析晚期卵巢癌患者行先期化疗联合术后腹腔热灌注化疗的临床效果、并发症及预后情况.方法 回顾性分析山西省肿瘤医院2015年5月至2017年5月收治的64例晚期卵巢癌患者临床资料,所有患者均行常规肿瘤细胞减灭手术（CDS）治疗.按照手术前后不同治疗方案将患者分成两组：先期化疗联合术后腹腔热灌注化疗32例作为观察组,单纯术后腹腔热灌注化疗32例作为对照组.比较两组临床效果、并发症及预后情况.结果 观察组失血量和腹腔积液量分别为（512±165）ml和（716±160）ml,均少于对照组的（815±186）ml和（1 279±236）ml,差异均有统计学意义（t值分别为6.890、11.153,均P＜0.05）.观察组手术用时为（125±15）min,短于对照组的（185±24）min,差异有统计学意义（t=18.572,P＜0.05）.观察组总并发症发生率和2年复发率低于对照组,2年生存率高于对照组,差异均有统计学意义（均P＜0.05）.结论 晚期卵巢癌者行先期化疗联合术后腹腔热灌注化疗效果较好,并发症少,预后佳,可推广应用.Objective To analyze the clinical effects, complications and prognosis of primary chemotherapy combined with postoperative intraperitoneal hyperthermic perfusion chemotherapy in the treatment of advanced ovarian cancer. Methods The clinical data of 64 patients with advanced ovarian cancer in Shanxi Provincial Cancer Hospital from May 2015 to May 2017 were analyzed retrospectively. Conventional cytoreductive surgery （CDS） was performed in all patients. According to the different therapeutic regimen before and after operation, the patients were divided into 2 groups, including 32 cases treated with primary chemotherapy combined with postoperative intraperitoneal hyperthermic perfusion chemotherapy （the observation group）, and 32 cases treated with intraperitoneal hyperthermic perfusion chemotherapy after operation （the control group）. The clinical effect, complications and prognosis were compared between the two groups. Results The blood loss in the observation group [（512±165） ml] was lower than that in the control group [（815±186） ml]. The amount of ascites in the observation group [（716±160） ml ] was lower than that in the control group [（1 279±236） ml], and the differences were statistically significant （t= 6.890, t= 11.153 respectively, both P〈 0.05）. Moreover, the duration of surgery in the observation group was shorter than that in the control group [（125 ±15） min vs. （185 ±24） min; t = 18.572, P〈 0.05]. The total incidence of complications and 2-year recurrence rate in the observation group were lower than those in the control group, and the 2-year survival rate in the observation group was higher than that in the control group （both P〈0.05）. Conclusion Primary chemotherapy combined with postoperative intraperitoneal hyperthermic perfusion chemotherapy for advanced ovarian cancer has a favorable effect with less complications and good prognosis, which is worthy of clinical application.

关 键 词：卵巢肿瘤 抗肿瘤联合化疗方案 腹腔热灌注化疗 手术后并发症 预后 

分 类 号：R737.31[医药卫生—肿瘤]